DD Support Board and Research Team

[shajandr]

Nott 2 change the topic, butt LLY has a blockbuster new drug subclass with very good data and solid (non-speculative) mechanism and an absolutely humongous market.

Dont know if the stock is a buy or if other fast-followers are in DaPipelines of others, butt FWIW ...

On a major bear market pullback, I may add it as another individual stock in a modest amount to DaShajandrKollective.

Never really liked Lilly before. Not even shure I like it now - plenny of mismanagement and this is only one drug in a huge pharma - butt it is gonna be a huge-mongous drug when approved. Even Lilly shouldn't be able to screw it up too badly as it will market itself.

I need to do more research on competition with fast-followers in their pipes. This will be a very important new subclass of drug.

Mebbe more on this when I CONduct the needed research. There should be plenny of time to buy in the bear market we are in and going deeper into.